medigraphic.com
ISSN 1561-3011 (Electronic)

2012, Number 2

<< Back Next >>

Rev Cubana Invest Bioméd 2012; 31 (2)

Catecholaminergic polymorphic ventricular tachycardia

Cruz CM

Language: Spanish
References: 44
Page: 187-198
PDF size: 135.35 Kb.


ABSTRACT

Catecholaminergic polymorphic ventricular tachycardia is a channelopathy characterized by the induction of polymorphic ventricular arrhythmias in the presence of catecholamines. It should be suspected in any young patient, especially a child or adolescent, presenting with syncope associated with physical exercise or emotional stress, with no structural heart disease and an ECG showing a normal QT interval. It is a rare disease, its importance lying in the high risk of sudden death, which may sometimes be its debut. Ventricular arrhythmias may be polymorphic or bidirectional. They are highly inducible by physical exercise and Isuprel infusion, their threshold is predictable and their complexity progressive. A family history of sudden death is reported in 30 to 40 % of patients. Two genetic mutations have been identified as causes of the condition (ryanodine receptor 2 with autosomal dominant inheritance and calsequestrin 2, with autosomal recessive inheritance). However, a causal mutation has been found in only 50-55 % of patients. Mutations influence sarcoplasmic reticulum Ca 2+ leak, facilitating the appearance of late post-depolarisations, which will in turn induce ventricular ectopic activity. Beta-blockers are the treatment of choice. The automatic implantable defibrillator is indicated in patients recovered from a sudden death event and in those who remain symptomatic despite medical therapy. Left cardiac sympathetic denervation, verapamil, flecainide and propafenone are alternative options for patients who remain symptomatic despite the use of beta-blockers.


REFERENCES

  1. Marks A, Priori S, Memmi M, Kontula K, Laitinen PJ. Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia J Cell Physiol. 2002;190:1-6.

  2. Reid DS, Tynan M, Braidwood L, Fitzgerald. Bidirectional tachycardia in a child. A study using His bundle electrography. Br Heart J. 1975;37:339-44.

  3. Coumel P, Fidelle J, Lucet V, Attuel P, Bouvrain Y. Catecholamine induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: Report of four cases. Br Heart J. 1978;40(Suppl):28-37.

  4. Dubner SJ, Gimeno GM, Elencwajg B et al. Ventricular fibrillation with spontaneous reversion on ambulatory ECG in the absence of heart disease. Am Heart J. 1983;105:691-3.

  5. Cohen TJ, Liem LB, Hancock EW. Association of bidirectional ventricular tachycardia with familial sudden death syndrome. Ain J Cardiol. 1989;64:1078- 9.

  6. De Paola AAV, Horowitz LN, Marques FB. Control of multiform ventricular tachycardia by propranolol in a child with no identifiable cardiac disease and sudden death. Am Heart J. 1990;119:1429-32.

  7. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 1995;91:1512-9.

  8. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia (CPVT).Circulation. 2002;106:69-74.

  9. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103:196-200.

  10. Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 2001;69:1378-84.

  11. Leite LR, Ponzi Pereira KR, Alessi SR, de Paola AAV. Catecholaminergic polymorphic ventricular tachycardia. An important diagnosis in children with syncope and normal heart. Arq Bras Cardiol. 2001;76:63-74.

  12. Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007;4(5):675-78.

  13. Fisher JD, Krikler D, Hallidie-Smith KA. Familial polymorphic ventricular arrhythmias: a quarter century of successful medical treatment based on serial exercise-pharmacologic testing. J Am Coll Cardiol. 1999;34:201522.

  14. Postma AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaksmann G, et al. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet. 2005;42:863-70.

  15. Aizawa Y, Komura S, Okada S, Chinushi M, Aizawa Y, Morita H, et al. Distinct U wave changes in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT). Int Heart J. 2006;47:3819.

  16. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation. 2001;103:48590.

  17. Jiang D, Wang R, Xiao B, Wang R, Choi P, Zhang L, et al. Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res. 2005;97:117381.

  18. George CH, Jundi H, Walters N, Thomas NL, West RR, Lai FA. Arrhythmogenic mutation-linked defects in ryanodine receptor autoregulation reveal a novel mechanism of Ca2+ release channel dysfunction. Circ Res. 2006;98:8897.

  19. George CH, Higgs GV, Lai FA. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res. 2003;93:53140.

  20. Liu N, Rizzi N, Boveri L. Ryanodine receptor and calsequestrin in arrhythmogenesis: what we have learn from genetic diseases and transgenic mice? J Mol Cell Cardiol. 2009;46:149-59.

  21. Di Barletta MR, Viatchenko-Karpinski S, Nori A, Memmi M, Terentyev D, Turcato F, et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2006;114:10129.

  22. Viatchenko-Karpinski S, Terentyev D, Gyorke I, Terentyeva R, Volpe P, Priori SG, et al. Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin. Circ Res. 2004;94: 471-7.

  23. Tester DJ, Arya P, Will M, Haglund CM, Farley AL, Makielski JC. et al. Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing. Heart Rhythm. 2006;3:800-5.

  24. Lehnart SE, Wehrens XH, Laitinen PJ, Reiken SR, Deng SX, Cheng Z, et al. Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation. 2004;109:3208-14.

  25. Cerrone M, Colombi B, Santoro M, di Barletta MR, Scelsi M, Villani L, et al. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ Res. 2005;96:e7782.

  26. Nam GB, Burashnikov B, Antzclevitch C. Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation. 2005;11:2727-33.

  27. Schwensen C. Ventricular tachycardia as the result of the administration of digitalis. Heart. 1922;9:199-204.

  28. Stubbs WA. Bidirectional ventricular tachycardia in familial hypokalaemic periodic paralysis. Proc R Soc Med. 1976;69:2234.

  29. Morita H, Zipes DP, Morita ST, Wu J. Mechanism of U wave and polymorphic ventricular tachycardia in a canine tissue model of Andersen-Tawil syndrome. Cardiovasc Res. 2007;75:510-8.

  30. Berte B, Eyskens B, Meyfroidt G, Willems R. Bidirectional ventricular tachycardia in fulminant myocarditis. Europace. 2008;10:7678.

  31. Rosenbaum MB, Elizari MV, Lazzari JO. The mechanism of bidirectional tachycardia. Am Heart J. 1969;78:2-4.

  32. Baher AA, Uy M, Xie F. Bidirectional ventricular tachycardia: Ping pong in the HisPurkinje system. Heart Rhythm. 2011;8:599-605.

  33. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 2003;89:66-70.

  34. Priori S, Schwartz PJ, Napolitano C. Risk Stratification in the Long-QT Síndrome. N Engl J Med. 2003;348:1866-74.

  35. Zhang L, Benson D.W, Tristani-Firouzi M. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-Uwave patterns predict the KCNJ2 genotype. Circulation. 2005;111:2720-6.

  36. Hayashi M, Denjoy I, Extramiana F. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119:2426-34.

  37. Fisher JD, Krikler D, Hallidie-Smith KA. Familial polymorphic ventricular arrhythmias. A quarter century of successful medical treatment based on serial exercisepharmacologic testing. J Am Coll Cardiol. 1999;34:2015-22.

  38. Heidbuchel H, Corrado D, Biffi A, Hoffmann E, Panhuyzen-Goedkoop N, Hoogsteen J, et al. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: ventricular arrhythmias, channelopathies and implantable defibrillators. Eur J Cardiovasc Prev Rehabil. 2006;13:676-86.

  39. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eurospace. 2006;8:746-837.

  40. Wilde AA, Bhuiyan ZA, Crotti L, Facchini M, De Ferrari GM, Paul T, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med. 2008;358:2024-9.

  41. Swan H, Laitinen P, Kontula K, Toivonen L. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol. 2005;16:1626.

  42. Rosso R, Kalman JM, Rogowski O, Diamant S, Birger A, Biner S, et al. Calcium channel blockers and beta blockers versus betablockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007;4:1149-54.

  43. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:3803.

  44. Hwang HS, Hasdemir C, Laver D, Mehra D, Turhan K, Faggioni M, et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circulation: Arrhythmia and Electrophysiology. 2011;4:128-35.




2020     |     www.medigraphic.com